AbbVie to Acquire Arizona Manufacturing Facility
AbbVie will acquire West Pharmaceutical Services’ Tempe, Arizona, manufacturing facility for over $175 million to expand US drug delivery device capacity, with closing expected mid-2026.
AbbVie and West Pharmaceutical Services announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona, and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie's drug delivery device manufacturing capabilities and capacity.
AbbVie plans to hire approximately 200 employees at the site and invest more than $175 million to acquire, as well as modernize and fully integrate it into its global manufacturing network. The combination of this acquisition and associated planned investments is part of AbbVie's commitment to expanding its pharmaceutical manufacturing in the US, supporting innovation and improving patient access and outcomes.
"Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the US," said Robert A. Michael, Chairman and Chief Executive Officer, AbbVie. "With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients' lives."
The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines.
The transaction is anticipated to close in mid-2026, subject to closing conditions.
